Clinical Trial Update: A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19 [Phase 2]

View source ↗

Summary

A Phase II clinical trial update for a treatment in patients with moderate to severe ARDS due to COVID-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Snippet

Sponsor: Stemedica Cell Technologies, Inc. | Conditions: Covid19 | Phase 2 | Status: UNKNOWN